236 related articles for article (PubMed ID: 26836429)
1. New Insulins, Biosimilars, and Insulin Therapy.
Danne T; Heinemann L; Bolinder J
Diabetes Technol Ther; 2016 Feb; 18 Suppl 1():S43-55. PubMed ID: 26836429
[No Abstract] [Full Text] [Related]
2. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
Godman B; Wladysiuk M; McTaggart S; Kurdi A; Allocati E; Jakovljevic M; Kalemeera F; Hoxha I; Nachtnebel A; Sauermann R; Hinteregger M; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Slabý J; Nejezchlebova R; Krulichová IS; Laius O; Selke G; Langner I; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuolienė K; Gulbinovič J; Bonanno PV; Rutkowski J; Ingeberg S; Melien Ø; Mardare I; Fürst J; MacBride-Stewart S; Holmes C; Pontes C; Zara C; Pedrola MT; Hoffmann M; Kourafalos V; Pisana A; Banzi R; Campbell S; Wettermark B
Biomed Res Int; 2021; 2021():9996193. PubMed ID: 34676266
[TBL] [Abstract][Full Text] [Related]
3. New Insulins, Biosimilars, and Insulin Therapy.
Danne T; Heinemann L; Bolinder J
Diabetes Technol Ther; 2020 Feb; 22(S1):S32-S46. PubMed ID: 32069160
[No Abstract] [Full Text] [Related]
4. New Insulins, Biosimilars, and Insulin Therapy.
Danne T; Heinemann L; Bolinder J
Diabetes Technol Ther; 2018 Feb; 20(S1):S55-S70. PubMed ID: 29437477
[No Abstract] [Full Text] [Related]
5. Ongoing efforts to improve the management of patients with diabetes in Bangladesh and the implications.
Haque M; Islam S; Kamal ZM; Akter F; Jahan I; Rahim MSA; Sultana N; Alam AM; Munzur-E-Murshid ; Halim-Khan MA; Deeba F; Bakar MA; Nahar S; Mozaffor M; Urmi UL; Saikat TR; Islam MZ; Haque M; Iqbal S; Hossain MM; Naher N; Allocati E; Godman B
Hosp Pract (1995); 2021 Oct; 49(4):266-272. PubMed ID: 33734004
[TBL] [Abstract][Full Text] [Related]
6. The future of basal insulin.
Shah VN; Moser EG; Blau A; Dhingra M; Garg SK
Diabetes Technol Ther; 2013 Sep; 15(9):727-32. PubMed ID: 23965036
[No Abstract] [Full Text] [Related]
7. Biosimilar products are not bioidentical.
Garber AJ
J Diabetes; 2015 Mar; 7(2):153-4. PubMed ID: 25395269
[No Abstract] [Full Text] [Related]
8. New Insulins, Biosimilars, and Insulin Therapy.
Danne T; Heinemann L; Bolinder J
Diabetes Technol Ther; 2019 Feb; 21(S1):S57-S78. PubMed ID: 30785319
[No Abstract] [Full Text] [Related]
9. Biosimilar Insulin and Costs: What Can We Expect?
Heinemann L
J Diabetes Sci Technol; 2015 Sep; 10(2):457-62. PubMed ID: 26350722
[TBL] [Abstract][Full Text] [Related]
10. Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future.
Godman B; Haque M; Kumar S; Islam S; Charan J; Akter F; Kurdi A; Allocati E; Bakar MA; Rahim SA; Sultana N; Deeba F; Halim Khan MA; Alam ABMM; Jahan I; Kamal ZM; Hasin H; Munzur-E-Murshid ; Nahar S; Haque M; Dutta S; Abhayanand JP; Kaur RJ; Acharya J; Sugahara T; Kwon HY; Bae S; Khuan KKP; Khan TA; Hussain S; Saleem Z; Pisana A; Wale J; Jakovljevic M
Curr Med Res Opin; 2021 Sep; 37(9):1529-1545. PubMed ID: 34166174
[TBL] [Abstract][Full Text] [Related]
11. Biosimilar vs originator insulins: Systematic review and meta-analysis.
Yamada T; Kamata R; Ishinohachi K; Shojima N; Ananiadou S; Nom H; Yamauchi T; Kadowaki T
Diabetes Obes Metab; 2018 Jul; 20(7):1787-1792. PubMed ID: 29536603
[TBL] [Abstract][Full Text] [Related]
12. The impact of biosimilar insulins on the diabetes landscape.
White J; Wagner A; Patel H
J Manag Care Spec Pharm; 2022 Jan; 28(1):91-98. PubMed ID: 34726499
[TBL] [Abstract][Full Text] [Related]
13. The evolution of insulin therapy in diabetes mellitus.
Heile M; Schneider D
J Fam Pract; 2012 May; 61(5 Suppl):S6-12. PubMed ID: 22577636
[No Abstract] [Full Text] [Related]
14. New Insulins, Biosimilars, and Insulin Therapy.
Danne T; Heinemann L; Bolinder J
Diabetes Technol Ther; 2017 Feb; 19(S1):S42-S58. PubMed ID: 28192016
[No Abstract] [Full Text] [Related]
15. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.
Godman B; Haque M; Leong T; Allocati E; Kumar S; Islam S; Charan J; Akter F; Kurdi A; Vassalo C; Bakar MA; Rahim SA; Sultana N; Deeba F; Khan MAH; Alam ABMM; Jahan I; Kamal ZM; Hasin H; Munzur-E-Murshid ; Nahar S; Haque M; Dutta S; Abhayanand JP; Kaur RJ; Rwegerera GM; do Nascimento RCRM; Dias Godói IP; Irfan M; Amu AA; Matowa P; Acolatse J; Incoom R; Sefah IA; Acharya J; Opanga S; Njeri LW; Kimonge D; Kwon HY; Bae S; Khuan KKP; Abubakar AR; Sani IH; Khan TA; Hussain S; Saleem Z; Malande OO; Piloya-Were T; Gambogi R; Hernandez Ortiz C; Alutuli L; Kalungia AC; Hoxha I; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Laius O; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuoliene K; Gulbinovič J; Wladysiuk M; Rutkowski J; Mardare I; Fürst J; McTaggart S; MacBride-Stewart S; Pontes C; Zara C; Tagoe ET; Banzi R; Wale J; Jakovljevic M
Front Public Health; 2021; 9():671961. PubMed ID: 34249838
[No Abstract] [Full Text] [Related]
16. Biosimilar insulins are coming: what they are, what you need to know.
Edelman S; Polonsky WH; Parkin CG
Curr Med Res Opin; 2014 Nov; 30(11):2217-22. PubMed ID: 25105307
[TBL] [Abstract][Full Text] [Related]
17. The advent of biosimilars for the treatment of diabetes: current status and future directions.
Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP
Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669
[TBL] [Abstract][Full Text] [Related]
18. New Insulins, Biosimilars, and Insulin Therapy.
Danne T; Heinemann L; Bolinder J
Diabetes Technol Ther; 2021 Jun; 23(S2):S46-S68. PubMed ID: 34061629
[No Abstract] [Full Text] [Related]
19. New Insulins, Biosimilars, and Insulin Therapy.
Danne T; Heinemann L; Pieber TR
Diabetes Technol Ther; 2023 Feb; 25(S1):S44-S69. PubMed ID: 36802184
[No Abstract] [Full Text] [Related]
20. Introduction of biosimilar insulins in Europe.
Davies M; Dahl D; Heise T; Kiljanski J; Mathieu C
Diabet Med; 2017 Oct; 34(10):1340-1353. PubMed ID: 28608570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
